Scholar Rock Holding Corp（SRRK）股票分析SRRKScholar Rock Holding Corp

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Scholar Rock Holding Corp (SRRK) is a good buy right now due to its recent FDA approval of ISEMBYLD, which has the potential to significantly increase revenue. The current price of $41.49 is well below the analyst price targets, suggesting a potential upside of 39% to 47%. Additionally, the stock has shown a 36.03% increase over the past year, indicating strong long-term growth potential. However, the company is facing substantial losses, with a net income of -$109,896,000 in Q2 2026, which remains a risk to consider.

4 analysts cover SRRK: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.